Telomir-Zn Shows Iron-Dependent Tumor Cell Mortality in Triple-Negative Breast Cancer Models
Telomir Pharmaceuticals reported that its Telomir-Zn compound induced near-complete mortality in MDA-MB-468 cells and significant mortality in HCC70 and MDA-MB-231 triple-negative breast cancer models in vitro, with iron-rescue assays confirming mechanism-driven tumor cell death. Supplemental iron reduced Telomir-Zn efficacy across completed subtypes, validating its metal-modulation approach.
1. Preclinical In Vitro Results
Telomir-Zn induced near-complete tumor cell death in MDA-MB-468 and significant mortality in HCC70 and MDA-MB-231 human triple-negative breast cancer cell lines over 72 hours, demonstrating efficacy across distinct molecular subtypes.
2. Iron-Dependent Mechanism
Iron-rescue assays showed supplemental iron significantly attenuated Telomir-Zn–induced cell death, confirming that tumor mortality is driven by disruption of intracellular iron dependency rather than nonspecific cytotoxicity.
3. IND-Enabling Progress
With two additional TNBC subtypes under evaluation, ongoing GLP safety studies in rats and dogs showing no treatment-related toxicity, and an IND submission scheduled for the first quarter of 2026, Telomir-Zn is advancing toward initial clinical trials.